Arix Bioscience
Presence
Arix Bioscience is a company listed under the stock ticker ARIX (GB).
Executives
View the org chart displaying its 6 main executives
Most searched biographies at Arix Bioscience
- Peregrine Moncreiffe, Chairman of the Board
- Andrew Smith, Independent Non-Executive Director
- Debra Barker, Senior Independent Director
Popular executive movements at Arix Bioscience
- Maureen O'Connell, Non-Executive Director, has left the company (posted on January 23 2024).
- Isaac Kohlberg, Non-Executive Director, has left the company (posted on January 23 2024).
- Robert Lyne, Chief Executive Officer and General Counsel, will leave the company in Jan. 2024 (posted on September 27 2023).
Create your alert
to follow the executive moves at Arix Bioscience.
Biotechnology
Arix Bioscience has 2,277 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (posted on April 16 2024).
Popular contacts in Biotechnology
News
Press releases by Arix Bioscience
- Financial update on Harpoon Therapeutics acquisition by Merck (MSD) - Arix Bioscience
- Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial - Arix Bioscience
- Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
- Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102 - Arix Bioscience
- Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023 | Harpoon Therapeutics, Inc.
- Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers | Disc Medicine Inc.
- Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting | Harpoon Therapeutics, Inc.
- Arix Interim Results for the Six Months Ended 30 June 2023 - Arix Bioscience
- Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September | Harpoon Therapeutics, Inc.
- View more press releases Close
Social media about Arix Bioscience
- Arix Bioscience on Wikipedia, Google News & Yahoo Finance
- Arix Bioscience on LinkedIn, Twitter & YouTube
